Antipsychotic Use and the risk of rhabdomyolysis

Kathleen A. Packard, Paul Price, Ashley Hanson

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Rhabdomyolysis is not a well-understood adverse effect of antipsychotic use. Proposed mechanisms suggest involvement of serotoninergic and/or dopaminergic blockade. The purpose of this study was to describe the relationship between antipsychotic use and rhabdomyolysis. Patients admitted with rhabdomyolysis and taking an antipsychotic from January 2009 to October 2011 were included. Background demographics, laboratory data, medical and physical history, concomitant medications, and hospital course data were collected. Of the 673 cases admitted with rhabdomyolysis, 71 (10.5%) were on an antipsychotic. This is significantly greater when compared to the general US population, where only 1.3% of individuals take an antipsychotic drug (P

Original languageEnglish
Pages (from-to)501-512
Number of pages12
JournalJournal of Pharmacy Practice
Volume27
Issue number5
DOIs
StatePublished - Oct 12 2014

Fingerprint

Rhabdomyolysis
Antipsychotic Agents
History
Demography
Population

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Antipsychotic Use and the risk of rhabdomyolysis. / Packard, Kathleen A.; Price, Paul; Hanson, Ashley.

In: Journal of Pharmacy Practice, Vol. 27, No. 5, 12.10.2014, p. 501-512.

Research output: Contribution to journalArticle

Packard, Kathleen A. ; Price, Paul ; Hanson, Ashley. / Antipsychotic Use and the risk of rhabdomyolysis. In: Journal of Pharmacy Practice. 2014 ; Vol. 27, No. 5. pp. 501-512.
@article{93a686c19db34ec7b4ed46fcfe37cac8,
title = "Antipsychotic Use and the risk of rhabdomyolysis",
abstract = "Rhabdomyolysis is not a well-understood adverse effect of antipsychotic use. Proposed mechanisms suggest involvement of serotoninergic and/or dopaminergic blockade. The purpose of this study was to describe the relationship between antipsychotic use and rhabdomyolysis. Patients admitted with rhabdomyolysis and taking an antipsychotic from January 2009 to October 2011 were included. Background demographics, laboratory data, medical and physical history, concomitant medications, and hospital course data were collected. Of the 673 cases admitted with rhabdomyolysis, 71 (10.5{\%}) were on an antipsychotic. This is significantly greater when compared to the general US population, where only 1.3{\%} of individuals take an antipsychotic drug (P",
author = "Packard, {Kathleen A.} and Paul Price and Ashley Hanson",
year = "2014",
month = "10",
day = "12",
doi = "10.1177/0897190013516509",
language = "English",
volume = "27",
pages = "501--512",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Antipsychotic Use and the risk of rhabdomyolysis

AU - Packard, Kathleen A.

AU - Price, Paul

AU - Hanson, Ashley

PY - 2014/10/12

Y1 - 2014/10/12

N2 - Rhabdomyolysis is not a well-understood adverse effect of antipsychotic use. Proposed mechanisms suggest involvement of serotoninergic and/or dopaminergic blockade. The purpose of this study was to describe the relationship between antipsychotic use and rhabdomyolysis. Patients admitted with rhabdomyolysis and taking an antipsychotic from January 2009 to October 2011 were included. Background demographics, laboratory data, medical and physical history, concomitant medications, and hospital course data were collected. Of the 673 cases admitted with rhabdomyolysis, 71 (10.5%) were on an antipsychotic. This is significantly greater when compared to the general US population, where only 1.3% of individuals take an antipsychotic drug (P

AB - Rhabdomyolysis is not a well-understood adverse effect of antipsychotic use. Proposed mechanisms suggest involvement of serotoninergic and/or dopaminergic blockade. The purpose of this study was to describe the relationship between antipsychotic use and rhabdomyolysis. Patients admitted with rhabdomyolysis and taking an antipsychotic from January 2009 to October 2011 were included. Background demographics, laboratory data, medical and physical history, concomitant medications, and hospital course data were collected. Of the 673 cases admitted with rhabdomyolysis, 71 (10.5%) were on an antipsychotic. This is significantly greater when compared to the general US population, where only 1.3% of individuals take an antipsychotic drug (P

UR - http://www.scopus.com/inward/record.url?scp=84904432531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904432531&partnerID=8YFLogxK

U2 - 10.1177/0897190013516509

DO - 10.1177/0897190013516509

M3 - Article

VL - 27

SP - 501

EP - 512

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 5

ER -